Can we eliminate placebo in ALS clinical trials?

Wilson W. Bryan, Rebecca J. Hoagland, J. Murphy, Carmel Armon, Richard J. Barohn, Jessie C. Goodpasture, Robert G. Miller, Gareth J. Parry, Jack H. Petajan, Mark A. Ross, Scott C. Stromatt, Jerry M. Belsh, Aron S. Buchman, Peter D. Donofrio, Andrew A. Eisen, Richard A. Gan, Laurie Gutmann, Steven H. Horowitz, Carlayne E. Jackon, Wendy S. JohnstonJohn J. Kelly, Raul N. Mandler, Janice M. Massey, Dawn McGuire, Daniel S. Newman, Robert M. Pascuzzi, Jack H. Petajan, Lawrence H. Phillips, Michael H. Rivner, Mark A. Rubin, Louis S. Russo, Stephen M. Sergay, Austin J. Sumner, Michael R. Swenson, Lawrence Teitel

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Previous studies concluded that the decline in strength in patients with amyotrophic lateral sclerosis (ALS) is a linear function. If so, a patient's natural history might serve as the control, instead of placebo, in a clinical trial. Methods: A placebo-controlled ALS clinical trial included a natural history phase, followed by a 6-month treatment phase. Each patient's forced vital capacity (FVC) score and maximal voluntary isometric contraction (MVIC) raw scores were measured monthly, standardized, and averaged into megascores. For 138 patients, the arm, leg, FVC, arm+leg combination, and arm+ leg+FVC combination megascore slopes during the natural history phase and during the placebo phase were compared. Results: The mean slope of megascores during the natural history phase and the mean slope during the placebo phase were not different for the arm, leg, and arm+leg megascores, but were different for the FVC and arm+leg+FVC combination megascores. Conclusions: Natural history controls may be useful in ALS exploratory trials that use arm megascore slope as the primary outcome measure. However, there are distinct limitations to the use of natural history controls, so that Phase 3 ALS clinical trials require placebo controls.

Original languageEnglish (US)
Pages (from-to)11-15
Number of pages5
JournalAmyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
Volume4
Issue number1
DOIs
StatePublished - Apr 2003

Fingerprint

Amyotrophic Lateral Sclerosis
Natural History
Arm
Vital Capacity
Placebos
Clinical Trials
Leg
Isometric Contraction
Outcome Assessment (Health Care)

Keywords

  • Amyotrophic lateral sclerosis
  • Motor neuron disease
  • Natural history
  • Neuromuscular diseases
  • Placebo

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Bryan, W. W., Hoagland, R. J., Murphy, J., Armon, C., Barohn, R. J., Goodpasture, J. C., ... Teitel, L. (2003). Can we eliminate placebo in ALS clinical trials? Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 4(1), 11-15. https://doi.org/10.1080/14660820310006661

Can we eliminate placebo in ALS clinical trials? / Bryan, Wilson W.; Hoagland, Rebecca J.; Murphy, J.; Armon, Carmel; Barohn, Richard J.; Goodpasture, Jessie C.; Miller, Robert G.; Parry, Gareth J.; Petajan, Jack H.; Ross, Mark A.; Stromatt, Scott C.; Belsh, Jerry M.; Buchman, Aron S.; Donofrio, Peter D.; Eisen, Andrew A.; Gan, Richard A.; Gutmann, Laurie; Horowitz, Steven H.; Jackon, Carlayne E.; Johnston, Wendy S.; Kelly, John J.; Mandler, Raul N.; Massey, Janice M.; McGuire, Dawn; Newman, Daniel S.; Pascuzzi, Robert M.; Petajan, Jack H.; Phillips, Lawrence H.; Rivner, Michael H.; Rubin, Mark A.; Russo, Louis S.; Sergay, Stephen M.; Sumner, Austin J.; Swenson, Michael R.; Teitel, Lawrence.

In: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, Vol. 4, No. 1, 04.2003, p. 11-15.

Research output: Contribution to journalArticle

Bryan, WW, Hoagland, RJ, Murphy, J, Armon, C, Barohn, RJ, Goodpasture, JC, Miller, RG, Parry, GJ, Petajan, JH, Ross, MA, Stromatt, SC, Belsh, JM, Buchman, AS, Donofrio, PD, Eisen, AA, Gan, RA, Gutmann, L, Horowitz, SH, Jackon, CE, Johnston, WS, Kelly, JJ, Mandler, RN, Massey, JM, McGuire, D, Newman, DS, Pascuzzi, RM, Petajan, JH, Phillips, LH, Rivner, MH, Rubin, MA, Russo, LS, Sergay, SM, Sumner, AJ, Swenson, MR & Teitel, L 2003, 'Can we eliminate placebo in ALS clinical trials?', Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 4, no. 1, pp. 11-15. https://doi.org/10.1080/14660820310006661
Bryan, Wilson W. ; Hoagland, Rebecca J. ; Murphy, J. ; Armon, Carmel ; Barohn, Richard J. ; Goodpasture, Jessie C. ; Miller, Robert G. ; Parry, Gareth J. ; Petajan, Jack H. ; Ross, Mark A. ; Stromatt, Scott C. ; Belsh, Jerry M. ; Buchman, Aron S. ; Donofrio, Peter D. ; Eisen, Andrew A. ; Gan, Richard A. ; Gutmann, Laurie ; Horowitz, Steven H. ; Jackon, Carlayne E. ; Johnston, Wendy S. ; Kelly, John J. ; Mandler, Raul N. ; Massey, Janice M. ; McGuire, Dawn ; Newman, Daniel S. ; Pascuzzi, Robert M. ; Petajan, Jack H. ; Phillips, Lawrence H. ; Rivner, Michael H. ; Rubin, Mark A. ; Russo, Louis S. ; Sergay, Stephen M. ; Sumner, Austin J. ; Swenson, Michael R. ; Teitel, Lawrence. / Can we eliminate placebo in ALS clinical trials?. In: Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2003 ; Vol. 4, No. 1. pp. 11-15.
@article{f462add3e0d740cc83d3916b62a913fe,
title = "Can we eliminate placebo in ALS clinical trials?",
abstract = "Background: Previous studies concluded that the decline in strength in patients with amyotrophic lateral sclerosis (ALS) is a linear function. If so, a patient's natural history might serve as the control, instead of placebo, in a clinical trial. Methods: A placebo-controlled ALS clinical trial included a natural history phase, followed by a 6-month treatment phase. Each patient's forced vital capacity (FVC) score and maximal voluntary isometric contraction (MVIC) raw scores were measured monthly, standardized, and averaged into megascores. For 138 patients, the arm, leg, FVC, arm+leg combination, and arm+ leg+FVC combination megascore slopes during the natural history phase and during the placebo phase were compared. Results: The mean slope of megascores during the natural history phase and the mean slope during the placebo phase were not different for the arm, leg, and arm+leg megascores, but were different for the FVC and arm+leg+FVC combination megascores. Conclusions: Natural history controls may be useful in ALS exploratory trials that use arm megascore slope as the primary outcome measure. However, there are distinct limitations to the use of natural history controls, so that Phase 3 ALS clinical trials require placebo controls.",
keywords = "Amyotrophic lateral sclerosis, Motor neuron disease, Natural history, Neuromuscular diseases, Placebo",
author = "Bryan, {Wilson W.} and Hoagland, {Rebecca J.} and J. Murphy and Carmel Armon and Barohn, {Richard J.} and Goodpasture, {Jessie C.} and Miller, {Robert G.} and Parry, {Gareth J.} and Petajan, {Jack H.} and Ross, {Mark A.} and Stromatt, {Scott C.} and Belsh, {Jerry M.} and Buchman, {Aron S.} and Donofrio, {Peter D.} and Eisen, {Andrew A.} and Gan, {Richard A.} and Laurie Gutmann and Horowitz, {Steven H.} and Jackon, {Carlayne E.} and Johnston, {Wendy S.} and Kelly, {John J.} and Mandler, {Raul N.} and Massey, {Janice M.} and Dawn McGuire and Newman, {Daniel S.} and Pascuzzi, {Robert M.} and Petajan, {Jack H.} and Phillips, {Lawrence H.} and Rivner, {Michael H.} and Rubin, {Mark A.} and Russo, {Louis S.} and Sergay, {Stephen M.} and Sumner, {Austin J.} and Swenson, {Michael R.} and Lawrence Teitel",
year = "2003",
month = "4",
doi = "10.1080/14660820310006661",
language = "English (US)",
volume = "4",
pages = "11--15",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Can we eliminate placebo in ALS clinical trials?

AU - Bryan, Wilson W.

AU - Hoagland, Rebecca J.

AU - Murphy, J.

AU - Armon, Carmel

AU - Barohn, Richard J.

AU - Goodpasture, Jessie C.

AU - Miller, Robert G.

AU - Parry, Gareth J.

AU - Petajan, Jack H.

AU - Ross, Mark A.

AU - Stromatt, Scott C.

AU - Belsh, Jerry M.

AU - Buchman, Aron S.

AU - Donofrio, Peter D.

AU - Eisen, Andrew A.

AU - Gan, Richard A.

AU - Gutmann, Laurie

AU - Horowitz, Steven H.

AU - Jackon, Carlayne E.

AU - Johnston, Wendy S.

AU - Kelly, John J.

AU - Mandler, Raul N.

AU - Massey, Janice M.

AU - McGuire, Dawn

AU - Newman, Daniel S.

AU - Pascuzzi, Robert M.

AU - Petajan, Jack H.

AU - Phillips, Lawrence H.

AU - Rivner, Michael H.

AU - Rubin, Mark A.

AU - Russo, Louis S.

AU - Sergay, Stephen M.

AU - Sumner, Austin J.

AU - Swenson, Michael R.

AU - Teitel, Lawrence

PY - 2003/4

Y1 - 2003/4

N2 - Background: Previous studies concluded that the decline in strength in patients with amyotrophic lateral sclerosis (ALS) is a linear function. If so, a patient's natural history might serve as the control, instead of placebo, in a clinical trial. Methods: A placebo-controlled ALS clinical trial included a natural history phase, followed by a 6-month treatment phase. Each patient's forced vital capacity (FVC) score and maximal voluntary isometric contraction (MVIC) raw scores were measured monthly, standardized, and averaged into megascores. For 138 patients, the arm, leg, FVC, arm+leg combination, and arm+ leg+FVC combination megascore slopes during the natural history phase and during the placebo phase were compared. Results: The mean slope of megascores during the natural history phase and the mean slope during the placebo phase were not different for the arm, leg, and arm+leg megascores, but were different for the FVC and arm+leg+FVC combination megascores. Conclusions: Natural history controls may be useful in ALS exploratory trials that use arm megascore slope as the primary outcome measure. However, there are distinct limitations to the use of natural history controls, so that Phase 3 ALS clinical trials require placebo controls.

AB - Background: Previous studies concluded that the decline in strength in patients with amyotrophic lateral sclerosis (ALS) is a linear function. If so, a patient's natural history might serve as the control, instead of placebo, in a clinical trial. Methods: A placebo-controlled ALS clinical trial included a natural history phase, followed by a 6-month treatment phase. Each patient's forced vital capacity (FVC) score and maximal voluntary isometric contraction (MVIC) raw scores were measured monthly, standardized, and averaged into megascores. For 138 patients, the arm, leg, FVC, arm+leg combination, and arm+ leg+FVC combination megascore slopes during the natural history phase and during the placebo phase were compared. Results: The mean slope of megascores during the natural history phase and the mean slope during the placebo phase were not different for the arm, leg, and arm+leg megascores, but were different for the FVC and arm+leg+FVC combination megascores. Conclusions: Natural history controls may be useful in ALS exploratory trials that use arm megascore slope as the primary outcome measure. However, there are distinct limitations to the use of natural history controls, so that Phase 3 ALS clinical trials require placebo controls.

KW - Amyotrophic lateral sclerosis

KW - Motor neuron disease

KW - Natural history

KW - Neuromuscular diseases

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=0038813879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038813879&partnerID=8YFLogxK

U2 - 10.1080/14660820310006661

DO - 10.1080/14660820310006661

M3 - Article

C2 - 12745612

AN - SCOPUS:0038813879

VL - 4

SP - 11

EP - 15

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 1

ER -